The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut

Anna Banerji; Vladimir Panzov; Michael Young; Bonita E Lee; Muhammad Mamdani; B Louise Giles; Marguerite Dennis; Johanne Morel; Danny Bisson; Bosco A Paes; Charles Hui; Jim Mahony

doi:10.1155/2014/941367

Canadian Respiratory Journal (Jan 2014)

The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut

Anna Banerji,
Vladimir Panzov,
Michael Young,
Bonita E Lee,
Muhammad Mamdani,
B Louise Giles,
Marguerite Dennis,
Johanne Morel,
Danny Bisson,
Bosco A Paes,
Charles Hui,
Jim Mahony

Affiliations

Anna Banerji: Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada
Vladimir Panzov: Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada
Michael Young: IWK Children’s Hospital, Halifax, Nova Scotia, Canada
Bonita E Lee: Provincial Public Health Laboratory, Edmonton Clinic Health Academy (ECHA), Edmonton, Alberta, Canada
Muhammad Mamdani: Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada
B Louise Giles: Winnipeg Children’s Hospital, Winnipeg, Manitoba, Canada
Marguerite Dennis: Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Johanne Morel: Montreal Children’s Hospital, Montreal, Quebec, Canada
Danny Bisson: JA Hildes Northern Medical Unit, Winnipeg, Manitoba, Canada
Bosco A Paes: Department of Pediatrics, McMaster University, Hamilton, Canada
Charles Hui: Children’s Hospital of Eastern Ontario, Ottawa, Canada
Jim Mahony: Regional Virology & Chlamydiology Laboratory, Department of Pathology and Molecular Medicine, McMaster University, St Joseph’s Healthcare, Hamilton, Ontario, Canada

DOI: https://doi.org/10.1155/2014/941367
Journal volume & issue: Vol. 21, no. 3
pp. 185 – 189

Abstract

Read online

BACKGROUND/OBJECTIVE: Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year <1 year of age. Palivizumab was implemented in Nunavut primarily for premature infants, or those with hemodynamically significant cardiac or chronic lung disease; however, the effectiveness of the program is unknown. The objective of the present multisite, hospital-based surveillance study was to estimate the effectiveness of palivizumab in infants <6 months of age in Nunavut for the 2009 and 2010 RSV seasons.

Published in Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://www.hindawi.com/journals/crj/

About the journal